- Home
- DYN vs TWST Comparison
DYN vs TWST Comparison
Compare DYN & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- TWST
- Stock Information
- Founded
- DYN 1984
- TWST 2013
- Country
- DYN United States
- TWST United States
- Employees
- DYN N/A
- TWST N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYN Health Care
- TWST Health Care
- Exchange
- DYN Nasdaq
- TWST Nasdaq
- Market Cap
- DYN 1.9B
- TWST 2.3B
- IPO Year
- DYN 2020
- TWST 2018
- Fundamental
- Price
- DYN $14.22
- TWST $25.76
- Analyst Decision
- DYN Strong Buy
- TWST Buy
- Analyst Count
- DYN 14
- TWST 9
- Target Price
- DYN $34.93
- TWST $50.67
- AVG Volume (30 Days)
- DYN 2.4M
- TWST 1.6M
- Earning Date
- DYN 07-28-2025
- TWST 08-04-2025
- Dividend Yield
- DYN N/A
- TWST N/A
- EPS Growth
- DYN N/A
- TWST N/A
- EPS
- DYN N/A
- TWST N/A
- Revenue
- DYN N/A
- TWST $362,273,000.00
- Revenue This Year
- DYN N/A
- TWST $22.28
- Revenue Next Year
- DYN N/A
- TWST $17.40
- P/E Ratio
- DYN N/A
- TWST N/A
- Revenue Growth
- DYN N/A
- TWST 22.72
- 52 Week Low
- DYN $6.36
- TWST $24.28
- 52 Week High
- DYN $37.08
- TWST $55.33
- Technical
- Relative Strength Index (RSI)
- DYN 73.48
- TWST 36.12
- Support Level
- DYN $13.03
- TWST $24.97
- Resistance Level
- DYN $13.85
- TWST $27.29
- Average True Range (ATR)
- DYN 0.64
- TWST 1.23
- MACD
- DYN 0.04
- TWST 0.10
- Stochastic Oscillator
- DYN 95.55
- TWST 20.73
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.